Dr. Bernie Zeiher, Astellas President of Development, explains in a new series of videos created by the Pharmaceutical Research and Manufacturers of America (PhRMA) how innovative companies are using biomarkers to advance personalized medicines and help improve outcomes for patients.
“Biomarkers are used in clinical studies to select patients eligible to be treated in that study,” explains Zeiher. “In the case of oncology, if you’re targeting a tumor that has a particular mutation, you’d run the test before they’re enrolled and see if they have that mutation, and if they are, they’re eligible for treatment.”
In November, Zeiher was profiled in a PhRMA video in which he discussed his highly personal entry into medicine, his reflections on more than 15 years in helping to develop innovative treatments, and his clear and unwavering optimism for the future. “The continuing motivation to bring therapies forward is there for me and hopefully for the whole industry,” Zeiher said. “I’m optimistic about the future because the promise of personalized medicines has begun to be seen.”